Back to Search
Start Over
Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study.
- Source :
- Cancer Communications; Jul2024, Vol. 44 Issue 7, p833-851, 19p
- Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 25233548
- Volume :
- 44
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Cancer Communications
- Publication Type :
- Academic Journal
- Accession number :
- 178533424
- Full Text :
- https://doi.org/10.1002/cac2.12577